Genomics, Inc. (NASDAQ:TXG – Get Free Report) has received a consensus recommendation of “Hold” from the seventeen analysts ...

Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by Morgan Stanley from $28.00 to $26.00 in a research ...

10x Genomics maintains strong fundamentals despite current headwinds. InvestingPro analysis indicates the stock is currently slightly undervalued based on its Fair Value model, offering potential ...

10x Genomics (NASDAQ:TXG), a leading player in the single-cell and spatial genomics technologies sector, finds itself at a critical juncture as it navigates through a challenging market environment.

The NIH projected the cut will save it $4 billion during the current federal fiscal year, which ends September 30. That’s ...